WOBURN, Mass.--(BUSINESS WIRE)--CryoXtract Instruments LLC, a provider of automated frozen aliquotting systems for high-value frozen biosamples, is pleased to introduce the CXT 353 Frozen Sample Aliquotter, the next generation semi-automated benchtop instrument for frozen aliquotting of a wide range of sample types including tissue, feces, plasma, whole blood, urine and other biofluids.
The CXT 353 features a compact benchtop design, user-friendly touch screen operation and compatibility with a wide range of vial types. The CXT 353 expands upon the company’s original CXT 350 solution with faster cycle times and actuated ejection, enhancing cold chain sample processing and increasing precision in core deposition.
“This is a welcome expansion to our product line that will especially meet the needs of researchers working with labile molecules,” said Graham Long, Vice President of Business Development and Marketing. “This new model allows greater flexibility to support a wider variety of research needs. We are excited to introduce customers to the enhanced functionality of the benchtop CXT 353.”
Other features of the CXT 353 include a removable guard for simplified cleaning, increased range of aliquot volumes (now 10-250μL) and a new 1.5 mm single-use coring probe that enables smaller core volumes for targeted tissue acquisition. As with the CXT 350, single-use probes in the CXT 353 prevent sample-to-sample carryover and contamination and the instrument’s laser-targeting feature enables coring of specific tissue sample regions, streamlining tissue processing within pathology workflows.
“The CXT 353 platform was developed in response to the needs of our customers and is a manifestation of our commitment to designing the best products on the market,” said CryoXtract Instruments Chief Executive Officer Dan Espinal.
The CXT 353 joins the company’s portfolio of bioanalytical solutions that also include the CXT 750 Automated Frozen Sample Aliquotter. The United States Patent Office (USPTO) recently granted to CryoXtract Instruments its first patent for the CXT 750, validating the assistance it offers with bioanalysis in drug discovery and development.
The new patent addresses the CXT 750’s ability to more accurately acquire specific, user-defined volumes from frozen samples. This unique functionality is particularly relevant to the bioanalysis of drug molecules for drug metabolism and pharmacokinetics and supports the effective use of frozen samples without exposing them to unnecessary, damaging freeze/thaw cycles.
CryoXtract Instruments’ solutions enable the automated extraction of multiple frozen cores from a single frozen sample while maintaining the parent and extracted samples at temperatures below -80°C. The ability to extract frozen aliquots while preserving the parent sample prevents degradation due to thawing and maximizes the use of critical samples such as rare disease, late-stage disease and pediatric samples. Frozen aliquotting helps to stabilize labile small molecule compounds, peptides and proteins for bioanalysis and preserves sample quality for additional testing or re-analysis.
CryoXtract Instruments will exhibit at the annual meeting of the Association for Molecular Pathology (AMP) in Austin, Texas from November 5th – 7th. The company will be showcasing its CXT 353 Frozen Sample Aliquotter at booth #101.
To learn more about the AMP conference, visit
For more information on CryoXtract Instruments, visit
About CryoXtract Instruments, LLC
CryoXtract develops and commercializes automation solutions that allow for the retrieval of multiple frozen samples from a single frozen biospecimen without exposing the source to the deleterious biological impact from freeze/thaw cycling. The company's automation technology system improves frozen biosample processing, protects the viability of frozen biosamples after cores have been extracted, improves lab efficiencies and economics, and helps optimize scientific outcomes. CryoXtract is a subsidiary of Boston-based Allied Minds, Inc. For more information, please visit www.cryoxtract.com.
About Allied Minds
Allied Minds (LSE: ALM) is an innovative U.S. science and technology development and commercialization company. Operating since 2006, Allied Minds forms, funds, manages and builds products and businesses based on innovative technologies developed at leading U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses and product development with capital, central management and shared services. More information about the Boston-based company can be found at www.alliedminds.com.
Allied Minds Forward-Looking Statement
This press release contains statements that are or may be forward-looking statements, including statements that relate to the company’s future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the company’s regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Listing Rules and the Disclosure and Transparency Rules, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.